Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.38 |
| ▸ | HINT1 | P49773 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TYMP | P19971 | 3/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565279 | 0.86 | HPGD (0.42) | NT5EHINT1IMPDH2HPGD | |
| SCHEMBL19128051 | 0.86 | HPGD (0.42) | NT5EHINT1IMPDH2HPGD | |
| SCHEMBL23384008 | 0.85 | HPGD (0.38) | NT5EHINT1IMPDH2HPGDGSK3A | |
| SCHEMBL19127926 | 0.84 | IMPDH2 (0.49) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL5960166 | 0.84 | IMPDH2 (0.49) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL19128883 | 0.84 | TYMP (0.49) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL14565276 | 0.83 | IMPDH2 (0.37) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL19128798 | 0.82 | IMPDH2 (0.42) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL7708569 | 0.82 | IMPDH2 (0.36) | NT5EHINT1IMPDH2HPGDTYMP | |
| SCHEMBL7708565 | 0.82 | IMPDH2 (0.36) | NT5EHINT1IMPDH2HPGDTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2020-05-28 | — | — | US | disclosed |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | INNATE TUMOR IMMUNITY, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumoir Immunity, Inc. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3402801-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumor Immunity, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123669-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | GLICK GARY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123669-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | GLICK GARY (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | NT5E 1878/4885HINT1 1249/4885IMPDH2 2269/4885 |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NT5E 1878/4885HINT1 1249/4885IMPDH2 2269/4885 |
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | NT5E 1878/4885HINT1 1249/4885IMPDH2 2269/4885 |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | STING1, CGAS, IRF3 | NT5E 179/4885HINT1 485/4885IMPDH2 180/4885 |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | STING1, CGAS, IRF3 | NT5E 179/4885HINT1 485/4885IMPDH2 180/4885 |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NT5E 1878/4885HINT1 1249/4885IMPDH2 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.